Neufeld G, Gospodarowicz D
Cancer Research Institute, University of California Medical Center, San Francisco 94143.
J Cell Physiol. 1988 Sep;136(3):537-42. doi: 10.1002/jcp.1041360321.
The fibroblast growth factor (FGF) receptor of human umbilical vein-derived endothelial (HUE) cells has been identified by affinity labeling. It has an apparent molecular weight of 130,000. It binds both basic and acidic FGF, but not with epidermal growth factor, insulin, or transferrin. The lectin concanavalin-A does not inhibit the binding of 125I-bFGF to HUE cell-surface receptors, whereas it inhibits bFGF binding to BHK-21 cell-surface FGF receptor. This suggests that both types of receptors may differ in their degree of glycosylation. In contrast to other cell types, heparin only slightly inhibits the binding of basic FGF to its receptor. Protamine sulfate, which is anti-angiogenic in vivo, and suramin, a drug used in the therapy of trypanosomiasis and onchocerciasis, also inhibit the binding of basic FGF to the receptor.
人脐静脉来源的内皮（HUE）细胞的成纤维细胞生长因子（FGF）受体已通过亲和标记鉴定出来。其表观分子量为130,000。它能结合碱性和酸性FGF，但不与表皮生长因子、胰岛素或转铁蛋白结合。凝集素伴刀豆球蛋白A不抑制125I-bFGF与HUE细胞表面受体的结合，而它能抑制bFGF与BHK-21细胞表面FGF受体的结合。这表明这两种受体的糖基化程度可能不同。与其他细胞类型不同，肝素仅轻微抑制碱性FGF与其受体的结合。硫酸鱼精蛋白在体内具有抗血管生成作用，苏拉明是一种用于治疗锥虫病和盘尾丝虫病的药物，它们也能抑制碱性FGF与受体的结合。
